Advances in Burkholderia cepacia complex

Paediatric Respiratory Reviews

Volumn 3, Issue 3, 2002, Pages 230-235

  Speert, David Paul ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antibiotic resistance; Biofilms; Burkholderia cepacia; Burkholderia cepacia complex; Chronic granulomatous disease; Cystic fibrosis; Epidemiology; Multiple combination antimicrobial testing; Quorum sensing

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; CARBAPENEM; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; MEROPENEM; MINOCYCLINE; PENICILLIN G; POLYMYXIN; QUINOLONE; TICARCILLIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; BACTERIAL SURVIVAL; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM IDENTIFICATION; BURKHOLDERIA CEPACIA; CHRONIC GRANULOMATOUS DISEASE; CONTROLLED STUDY; CYSTIC FIBROSIS; DEATH; HOST CELL; HOST SUSCEPTIBILITY; HUMAN; IMMUNE DEFICIENCY; NEUTROPHIL; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; TAXONOMY;

EID: 0036418961     PISSN: 15260550     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-0542(02)00185-9     Document Type: Review

References (47)

1. Burkholder WH. Sour skin, a bacterial rot of onion bulbs. Phytopathology 1950; 40: 115-117.
2. Isles A, Maclusky I, Corey M et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 1984; 104: 206-210.
3. Winkelstein JA, Marino MC, Johnston RB Jr et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine 2000; 79: 155-169.
4. Johnston RB Jr. Clinical aspects of chronic granulomatous disease. Curr Opin Hematol 2001; 8: 17-22.
5. LiPuma JJ, Dasen SE, Nielson DW, Stern RC, Stull TL, Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet 1990; 336: 1094-1096.
6. Parke JL, Gurian-Sherman D. Diversity of the Burkholderia cepacia complex and implications for risk assessment of biological control strains. Annu Rev Phytopathol 2001; 39: 225-258.
7. LiPuma JJ. Burkholderia cepacia: management issues and new insights. Clin Chest Med 1998; 19: 473-486, vi.
8. Babior BM, Kipnes RS, Curnutte JT. The production by leukocytes of superoxide, a potential bactericidal agent. J Clin Invest 1973; 52: 744-751.
9. Quie PG, White JG, Holmes B, Good RA. In vitro bactericidal capacity of human polymorphonuclear leukocytes: diminished activity in chronic granulomatous disease of childhood. J Clin Invest 1967; 46: 668-679.
10. Speert DP, Bond M, Woodman RC, Curnutte JT. Infection with Pseudomonas cepacia in chronic granulomatous disease: role of nonoxidative killing by neutrophils in host defense. J Infect Dis 1994; 170: 1524-1531.
11. Rommens JM, Iannuzzi MC, Kerem B et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989: 245: 1059-1065.
12. Speert DP. Pseudomonas aeruginosa infections in patients with cystic fibrosis. in Smith RP (ed) Pseudomonas aeruginosa Infections and Treatment. New York: Marcel Dekker, Inc., 1994, pp. 183-236.
13. Learn DB, Brestel EP, Seetharama S. Hypochlorite scavenging by Pseudomonas aeruginosa alginate. Infect Immun 1987; 55: 1813-1818.
14. Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 1996; 143: 1007-1017.
15. Snell GI, de Hoyos A, Krajden M, Winton T, Maurer JR. Pseudomonas cepacia in lung transplant recipients with cystic fibrosis. Chest 1993; 103: 466-471.
16. Aris RM, Routh JC, LiPuma JJ, Heath DG, Gilligan PH, Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med 2001; 164: 2102-2106.
17. Yabuuchi E, Kosalko Y, Oyaizu H et al. Proposal of Burkholderia gen. nov. and transfer of seven species of the genus Pseudomonas homology group II to the new genus with the type species Burkholderia cepacia (Palleroni and Holmes 1981) comb. nov. Microbiol Immunol 1992; 36: 1251-1275.
18. Vandamme P, Holmes B, Vancanneyt M. Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int J Syst Bacteriol 1997; 47: 1188-1200.
19. Speert DP, Henry DA, Vandamme P, Corey M, Mahenthiralingam E. Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada. Emerg Infect Dis 2002; 8: 181-187.
20. Coenye T, Vandamme P, Govan JR, LiPuma JJ. Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol 2001; 39: 3427-3436.
21. Henry DA, Campbell ME, LiPuma JJ, Speert DP. Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium. J Clin Microbiol 1997; 35: 614-619.
22. McMenamin JD, Zaccone TM, Coenye T, Vandamme P, LiPuma JJ. Misidentification of Burkholderia cepacia in US cystic fibrosis treatment centers: an analysis of 1051 recent sputum isolates. Chest 2000; 117: 1661-1665.
23. Burdge DR, Noble MA, Campbell ME, Krell VL, Speert DP. Misidentifcation of Xonthamonas maltophilia as Pseudomonas cepacia in the sputum of patients with cystic fibrosis: a diagnostic pitfall with major clinical implications. Clin Infect Dis 1994; 20: 445-448.
24. LiPuma JJ. Burkholderia cepacia epidemiology and pathogenesis: implications for infection control. Curr Opin Pulm Med 1998; 4: 337-341.
25. Mahenthiralingam E, Vandamme P, Campbell ME et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III car replace Burkholderia multivorans. Clin Infect Dis 2001; 33: 1469-1475.
26. Speert DP and the International Pseudomonas aeruginosa Typing Group. A multicenter comparison of methods for typing Pseudomonas aeruginosa predominantly from patients with cystic fibrosis. J Infect Dis 1994; 169: 134-142.
27. Sun L, Jiang R, Steinbach S et al. The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain. Nat Med 1995; 1: 661-666.
28. Sajjan US, Sylvester FA, Forstner JF. Cable-piliated Burkholderia cepacia binds to cytokeratin 13 of epithelial cells. Infect Immun 2000; 68: 1787-1795.
29. Mahenthiralingam E, Simpson DA, Speert DP. Identification and characterization of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis. J Clin Microbiol 1997; 35: 808-816.
30. LiPuma JJ, Mortensen JE, Dasen SE et al. Ribotype analysis of Pseudomonas cepacia from cystic fibrosis treatment centers. J Pediatr 1988; 113: 859-862.
31. Govan JR, Brown PH, Maddison J et al. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 1993; 342: 15-19.
32. Paul ML, Pegler MA, Benin RA. Molecular epidemiology of Burkholderia cepacia in two Australian cystic fibrosis centres. J Hosp Infect 1998, 38: 19-26.
33. Agodi A, Mahenthiralingam E, Barchitta M, Giannino V, Sciacca A, Stefani S. Burkholderia cepacia complex infection in Italian patients with cystic fibrosis: prevalence, epidemiology, and genomovar status. J Clin Microbiol 2001; 39: 2891-2896.
34. Nelson JW, Butler SL, Krieg D, Govan JR. Virulence factors of Burkholderia cepacia. FEMS Immunol Med Microbiol 1994; 8: 89-97.
35. Wongwanich S, Chotanachan P, Kondo E, Kanai K. Multifactorial pathogenic mechanisms of Burkholderia pseudomallei as suggested from comparison with Burkholderia cepacia. Southeast Asian J Trop Med Public Health 1996; 27: 111-118.
36. Burns JL, Jonas M, Chi EY, Clark DA, Berger A, Griffith A. Invasion of respiratory epithelial cells by Burkholderia (Pseudomonas) cepacia. Infect Immun 1996; 64: 4054-4059.
37. Chiu CH, Ostry A, Speert DP. Invasion of murine respiratory epithelial cells in vivo by Burkholderia cepacia. J Med Microbiol 2001; 50: 594-601.
38. Cieri MV, Mayer-Hamblett N, Griffith A, Burns JL. Correlation between an in vitro invasion assay and a murine model of Burkholderia cepacia lung infection. Infect Immun 2002; 70: 1081-1086.
39. Saini LS, Galsworthy SB, John MA, Valvano MA. Intracellular survival of Burkholderia cepacia complex isolates in the presence of macrophage cell activation. Microbiology 1999; 145: 3465-3475.
40. Marolda CL, Hauroder B, John MA, Michel R, Valvano MA. Intracellular survival and saprophytic growth of isolates from the Burkholderia cepacia complex in free-living amoebae. Microbiology 1999; 145: 1509-1517.
41. Aaron SD, Ferris W, Henry DA, Speert DP, Macdonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000; 161: 1206-1212.
42. Donlan RM. Biofilm formation: a clinically relevant microbiological process. Clin Infect Dis 2001; 33: 1387-1392.
43. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001: 358: 135-138.
44. Riedel K, Hentzer M, Gelsenberger O et al. N-Acylhomoserine-lactone-mediated communication between Pseudomonas aeruginosa and Burkholderia cepacia in mixed biofilms. Microbiology 2001; 147: 3249-3262.
45. Lewenza S, Conway B, Greenberg EP, Sokol PA. Quorum sensing in Burkholderia cepacia: identification of the LuxRI homologs CepRI. J Bacteriol 1999; 181: 748-756.
46. Huber B, Riedel K, Hentzer M et al, The Cep quorum-sensing system of Burkholderia cepacia HIII controls biofilm formation and swarming motility. Microbiology 2001; 147: 2517-2528.
47. Cox AD, Wilkinson SG. Ionizing groups in lipopolysaccharides of Pseudomonas cepacia in relation to antibiotic resistance. Mol Microbiol 1991; 5: 641-646.